Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp (NYSE:XON) stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) stock performance was 12.84% in last session and finished the day at $17.49. Traded volume was 1.93million shares in the last session and the average volume of the stock remained 845.13K shares. Intrexon Corp (NYSE:XON) insider ownership is 0.30%.

Gilead and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) carry a Zacks Rank #1 (Strong Buy), Alexion is a Zacks Rank #2 (Buy) stock. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rose 2.01 percent to $7.62 Wednesday on volume of 1.36million shares. The intra-day range of the stock was $7.33 to $7.97. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has a market capitalization of $499.74million.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) slumped -8.98% following the company’s first quarter earnings release. For the quarter, Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported a 76% increase in revenue, hitting $8.1 million, driven by collaborative revenue derived from three agreements. Net loss, however, widened slightly to $7.6 million, or $0.12 per share — from $6.9 million, or $0.13 per share, in the prior-year period — as research and development expenses jumped to $12 million from $8.2 million. Sangamo Biosciences, Inc. (NASDAQ:SGMO)’s stock on May 14, 2014 reported a increase of 4.48% to the closing price of $13.30. Its fifty two weeks range is $6.86 -$24.69. The total market capitalization recorded $903.86million. The overall volume in the last trading session was 1.31million shares. In its share capital, SGMO has 67.96million outstanding shares.

Osiris Therapeutics Inc. (NASDAQ:OSIR) halved its losses and more than doubled revenue in the first quarter as it pursues the sale of stem cell therapies for wound care as well as orthopedic and sports medicine. The Columbia company lost $1.4 million on $10.1 million in sales in the three months ended March 31, compared with a $2.7 million loss on $4.1 million in sales in the same period of 2013. Its loss of 4 cents per share in the first quarter beat Wall Street analysts’ estimates of a loss of 7 cents per share. On Wednesday, shares of Osiris Therapeutics, Inc. (NASDAQ:OSIR) advanced 9.13% to close the day at $16.37. Company return on investment (ROI) is -1.90% and its monthly performance is recorded as 29.00%. Osiris Therapeutics, Inc. (NASDAQ:OSIR) quarterly revenue growth is 0.68%.